GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane

May 6, 2026 09:39 AM EDTUpdated 10:03 AM DealsChinaPharma GSK goes to Chi­na for $1B siR­NA deal in Ar­row­head­'s obe­si­ty lane Kyle LaHucik Biotech Correspondent GSK is fur­ther delv­ing in­to the car­diometa­bol­ic space — and deep­en­ing its re­la­tion­ship with Chi­na biotechs — in a $1 bil­lion biobucks deal with an siR­NA start­up. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER